Form 4 for CRL Charles River Laboratories
Accepted 2023-06-02 00:00:00 ET · period of report 2023-05-31 · accession 0001127602-23-017435 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-02 | 2023-05-31 | CRL | MACKAY MARTIN | Dir | A - Grant | $0.00 | +338 | 11.5K | +3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-31 | A | A | 338 | $0.00 | 11,505 | D | — | — | (F1) The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest upon the earlier of 5/15/2023 or the business day prior to the Company's next annual meeting of shareholders. |